Pfizer buys remaining 78% stake in gene therapy firm Bamboo Therapeutics
As it strives to become a leading gene therapy player, Pfizer Inc. acquired the remaining 78% of Bamboo Therapeutics Inc. (rare diseases related to neuromuscular and central nervous system conditions) it did not already own.
- Gene Therapy, Cell Therapy
- Acquisition of Private Biotech
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com